Table 1 Patient characteristics

From: Efficacy and safety of imatinib mesylate (Glivec™) in combination with interferon-α (IFN-α) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)

Patient Age (years) Sex Breakpoint Subtype ALL Prior chemotherapy Status at imatinib start Response to single-agent imatinib
1 64 M e1a2 pre-B ind.I+II, CNS-irr., cons.I, reind.* First relapse CHR, MRD+
2 60 F e1a2 pre-B Pre-B ind.I, CNS-irr. CR1, MRD+
3 74 M e1a2 c-ALL ind.I* CR1, MRD+ CHR, MRD+
4 47 F e1a2 c-ALL ind.I, imatinib, RIT+TBI/CY+allo-SCT(TCD) First relapse CMR, MRD+
5 71 F e1a2 c-ALL ind.I* Primary refractory CHR, MRD+
6 62 F e1a2 c-ALL ind.I+II, CNS-irr., cons.I, HD-TT+Mel+ASCT, maintenance: 6-MP+MTX, low-dose IFN-α First relapse Imatinib refractory d14
  1. Ind.I+II, cons.I=induction chemotherapy phases I and II and consolidation according to GMALL protocol 06/99; CNS-irr.=CNS irradiation; HD-TT+Mel=high-dose thiotepa and melphalan; ASCT=autologous stem cell transplantation.
  2. *=chemotherapy according to GMALL-elderly protocol; RIT+TBI+CY=radioimmunotherapy, total body irradiation,cyclophosphamide; allo-SCT=allogeneic stem cell transplantation; TCD=T-cell depletion; CR1=first complete remission; MRD+=evidence of minimal residual disease by TaqMan-PCR; CHR=complete hematologic response; CMR=complete marrow response.